GlaxoSmithKline (Ireland) Ltd.

Primary objective: To evaluate the effectiveness of belimumab compared with placebo on standard treatment in slowing the decline of lung volume in DCSSC-ILD subjects Key secondary objectives: To evaluate the effectiveness of belimumab compared with placebo on standard treatment in reducing the degree of skin thickening at week 52 in DCSSC-ILD subjects To evaluate the effectiveness of belimumab compared with placebo on standard treatment in reducing fatigue in DCSSC-ILD subjects. To evaluate the effectiveness of belimumab compared with placebo on standard treatment in slowing the progression of SSC or reducing mortality in DCSSC-ILD subjects

1) Primary objective (pharmacokinetics): To evaluate the exposure of belimumab after administration of 200 mg SC belimumab in Chinese pediatric SLE subjects who had previously received belimumab IV treatment; 2) Secondary objective (safety): To evaluate the safety and tolerability of 200 mg SC belimumab in pediatric SLE subjects who had previously received belimumab IV treatment.

Primary objective (safety): To describe the long-term safety profile of GSK3511294 100 mg (SC, once every 26 weeks) added to existing asthma treatment in subjects with eosinophilic severe asthma during the 12-month open-label extension period. Secondary objective (efficacy): To evaluate the effects of long-term administration of GSK3511294 100 mg (SC, once every 26 weeks) added to existing asthma treatment during the 12-month open-label extension period on a range of clinical markers of asthma control and additional efficacy assessments. Other objectives: 1. To describe the long-term safety profile of GSK3511294 100 mg (SC, once every 26 weeks) added to existing asthma treatment in subjects with eosinophilic severe asthma during the 12-month open-label extension period. 2. To evaluate the effects of long-term administration of GSK3511294 on the patients' asthma severity scale. Pharmacodynamic (PD) objective: To evaluate the long-term PD effects of GSK3511294. Healthcare resource utilization endpoint Objective: To further evaluate the effect of GSK3511294 100 mg SC on healthcare resource utilization.